logo

For the Inventor, By the Inventor

Lahntal, Germany

Gerd Zettlmeissl

This inventor holds 9 USPTO granted patents. Top assignees: Behringwerke Aktiengesellschaft, Aventis Behring Gmbh, Sanofi-Arentideutschland Gmbh. Active years: 1995-2007.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Gerd Zettlmeissl. Retrieved from https://idiyas.com/inventor/gerd-zettlmeissl

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9

% Patents Active = 100.0

Average Co-Inventor Count = 3.3

ph-index = 4

Forward Citations = 95(Granted Patents)


Location History:

  • Lahntal, DE (1995 - 2007)
  • Wetter, DE (1997 - 2007)

Company Filing History:

goldMedal4 out of 340 
 
Behringwerke Aktiengesellschaft
 patents
silverMedal3 out of 57 
 
Aventis Behring Gmbh
 patents
bronzeMedal1 out of 1 
 
Sanofi-Arentideutschland Gmbh
 patent
4. 1 out of 3,076 
 
The General Hospital Corporation
 patents
5. 1 out of 10 
 
Zlb Behring Gmbh
 patents
where one patent can have more than one assignee

Years Active: 1995-2007

Loading Chart...
9 patents (USPTO):Explore Patents
1. 7253264 - Immunoglobulin fusion proteins, their production and use (2007-08-07),
2. 7220556 - Preparation of factor XIIIa by gene manipulation (2007-05-22),
3. 6869790 - Preparation of DNA encoding factor XIIIA (2005-03-22),
4. 6746866 - Preparation of factor XIIIa by gene manipulation (2004-06-08),
5. 6207877 - Transgenic coagulation factor XIII defective animal and its use for testing wound healing and bleeding (2001-03-27),
6. 5700663 - Mutants of human antithrobin III and methods for their production (1997-12-23),
7. 5639597 - Cell-free receptor binding assays, the production and use thereof (1997-06-17),
8. 5618713 - Mutants of human antithrombin III (1997-04-08),
9. 5457089 - Muteins of human erythropoietin, the preparation thereof and the use (1995-10-10),

Title: Gerd Zettlmeissl: Innovator in Biopharmaceuticals

Introduction

Gerd Zettlmeissl is a notable inventor based in Lahntal, Germany. He has made significant contributions to the field of biopharmaceuticals, holding a total of nine patents. His work primarily focuses on the development of innovative proteins and diagnostic aids.

Latest Patents

One of Zettlmeissl's latest patents is related to immunoglobulin fusion proteins, which are genetically engineered soluble fusion proteins composed of human proteins not belonging to the immunoglobulin family. This invention highlights the surprising retention of functional properties in the fusion protein. Another significant patent involves the preparation of factor XIIIa through gene manipulation. This process utilizes cDNA isolated from human placenta, allowing for the high-purity production of factor XIIIa and the development of diagnostic aids for analyzing genetic defects.

Career Highlights

Throughout his career, Zettlmeissl has worked with prominent companies in the biopharmaceutical sector, including Behringwerke Aktiengesellschaft and Aventis Behring GmbH. His expertise in protein engineering and gene manipulation has positioned him as a key figure in the development of therapeutic solutions.

Collaborations

Zettlmeissl has collaborated with notable colleagues such as Ulrich Grundmann and Egon Amann. These partnerships have further enhanced his research and innovation in the field.

Conclusion

Gerd Zettlmeissl's contributions to biopharmaceuticals through his patents and collaborations underscore his role as a leading inventor in the industry. His work continues to impact the development of innovative medical solutions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…